Because of their large size compared to small molecules and their multifunctionality, nanoparticles (NPs) hold promise as biomedical imaging, diagnostic, and theragnostic agents. However, the key to their success hinges on a detailed understanding of their behavior after administration into the body. NP biodistribution, target binding, and clearance are complex functions of their physicochemical properties in serum, which include hydrodynamic diameter, solubility, stability, shape and flexibility, surface charge, composition, and formulation. Moreover, many materials used to construct NPs have real or potential toxicity or may interfere with other medical tests. In this review, we discuss the design considerations that mediate NP behavior in the body and the fundamental principles that govern clinical translation. By analyzing those nanomaterials that have already received regulatory approval, most of which are actually therapeutic agents, we attempt to predict which types of NPs hold potential as diagnostic agents for biomedical imaging. Finally, using quantum dots as an example, we provide a framework for deciding whether an NP-based agent is the best choice for a particular clinical application.
Definition of Nanotechnology
The US Food and Drug Administration (FDA) has not established its own formal definition of ''nanotechnology'' and currently relies on definitions provided by the National Nanotechnology Initiative (NNI). 1 When determining whether a new diagnostic or therapeutic agent should be considered a ''nanomaterial,'' the Center for Drug Evaluation and Research (CDER) within the FDA applies the following three NNI criteria: (1) research and technology development at the atomic, molecular, or macromolecular levels, in the length scale of approximately 1 to 100 nm range; (2) creating and using structures, devices, and systems that have novel properties and functions because of their small and/or intermediate size; and (3) ability to control or manipulate at the atomic scale. 2 Meeting these criteria are a variety of nanoparticle (NP) systems that span the range from a few nanometers to hundreds of nanometers ( Figure 1 ). In many cases, new physical, chemical, and biologic properties emerge at this nanoscale compared to bulk materials or single atoms. 1 When such NPs are applied to clinical problem solving, the National Institutes of Health (NIH) often uses the term ''nanomedicine.'' [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] It should be emphasized, though, that from the FDA's perspective, nanomaterials are regulated like any other new diagnostic or therapeutic agent. Clinical translation of NPs must adhere to the same principles of biodistribution, clearance, and toxicology that mediate small molecules and biologic agents, as well as satisfy additional concerns, as described below. Unfortunately, many fundamental questions about NPs delineated in 2005 by Whitesides 15 remain unanswered, including how NPs enter the body, how they are taken up by the cell, how they are distributed and eliminated in the body, and how they affect human health.
with contrast agents (ie, theragnostics). 17 It is precisely the large size of NPs, though, and the relationship between size and normal physiology that make clinical translation of NPs so difficult. In this review, we focus on the design considerations of NPs for biomedical imaging and diagnostics, but the principles apply equally to therapeutic agents and theragnostics.
In general, NPs fall into two distinct classes, those that are purely organic and those that are composed of an inorganic core (and sometimes shell) and then encased with a biocompatible organic coating (Table 1 ). This allimportant organic coating renders the NP soluble and stable in serum and determines its final hydrodynamic diameter (HD), as well as its final surface charge.
Design Considerations in the Context of Human Physiology Key Design Parameters for In Vivo Imaging
Like any contrast agent used for biomedical imaging, NPs must be designed to have a reasonable blood half-life, minimal nonspecific binding and uptake, selective binding to desired epitopes, such as cell surface receptors, effective elimination from the body (when NP components have any potential for toxicity), a high SBR, and little or no toxicity. 5, 10, 17 In general, the physiologic behavior and pharmacokinetic parameters of NPs can be optimized by adjusting their HD, composition, shape, and surface characteristics, such as charge and hydrophobicity, which are also key mediators of potential cytotoxicity and in vivo toxicity. [18] [19] [20] [21] [22] The contribution of each is described below.
Routes of Administration and NP Biodistribution
Over the past decade, multifunctional NPs have been investigated for use in oral delivery, pulmonary delivery, ocular delivery, transdermal delivery, and traversing the blood-brain barrier (BBB). 23 Oral delivery of proteins, peptides, genes, and vaccines is traditionally difficult owing to poor permeability and stability in the gastrointestinal tract. However, by encapsulating these biologic materials in a protective, ligand-targeted, site-specific NP carrier, they can be delivered to the intestine or the colon, where an external stimulus, such as temperature or pH, can trigger the release of the diagnostic or therapeutic agent. 24 In addition, increased surface area and decreased particle size can lead to increased mucoadhesion, which can increase gastrointestinal transit time and lead to increased bioavailability. 25, 26 Pulmonary delivery of nebulized NPs carrying immunosuppressants, either through inhalation or direct instillation into the trachea, has shown a greater therapeutic efficacy in preventing acute lung transplant rejection. 27, 28 However, the mechanisms underlying transpulmonary transport of NPs are only now being understood. 29 Because of the tight blood-retina barrier, systemic delivery of drugs to the retina is inefficient. However, direct administration of sustained-release NPs improves ocular residency and treatment efficacy. 30 Similarly, transdermal delivery of membrane permeable NPs helps control the release pattern and rate of delivery of drugs into skin and hair folicles. 31 Finally, certain NPs appear to cross the BBB by either passive diffusion or carrier-mediated transcytosis. 32 On the one hand, this observation can be exploited to help solve the long-standing problem of drug delivery to the central nervous system (CNS) using receptor-specific, monoclonal antibodyconjugated NPs. 33 On the other hand, it increases the potential for CNS toxicity after NP administration (see below).
For biomedical imaging, the preferred route of delivery is intravenous injection. However, the average size of capillary pores in normal tissues is only < 5 nm. 34, 35 Thus, small molecules equilibrate rapidly between intravascular and extravascular spaces, but NPs do not. As a frame of ultraviolet.
*EPR is desired for passive targeting systems but undesirable for active targeting systems.
Nanoparticles for Biomedical Imaging reference, an IgG molecule, which has an HD in its long dimensions of <10 nm, can take up to 24 hours to equilibrate between the blood and extracellular space and up to 4 days to adequately clear after binding its target. 36, 37 These same principles mediate the intravascular/extravascular equilibration of NPs. 38 And when the organic coating is inadequate, NPs circulating in the blood will be removed rapidly by the reticuloendothelial system (RES; see below). 39 Depending on the organic coating surrounding the NPs, nonspecific adsorption of plasma proteins, mostly albumin, can also increase effective HD and thus extravasation. 9, 20 Only neutral or certain hydrophilic surfaces (eg, zwitterionic) and neutral surfaces can prevent plasma protein adsorption. 18, 20, 40 In summary, intravenous injection ensures that an NP can potentially have access to the entire body, but normal vascular physiology will restrict NP biodistribution and significantly lengthen the time required for intravascular/extravascular equilibration.
Renal and Hepatic Clearance of NPs
Although some small molecules and salts can be excreted (ie, eliminated) from the body through salivary glands and sweat, the majority of clearance for small molecules and NPs injected into the bloodstream is through either renal (urine) or hepatic (bile to feces) routes. Renal filtration of the blood is mediated by the slit structure of the glomerular basement membrane (GBM). The slit diaphragm is approximately 43 nm in diameter, but the physiologic pore size is significantly smaller, < 5 nm in diameter. 41, 42 The physicochemical properties of NPs in serum, such as HD, dispersity, shape, flexibility, and surface charge, will determine whether an NP can be renally filtered. 20, 39, 43 Globular NPs with an HD , 6 nm are typically filtered and are eliminated from the body in urine, whereas those with an HD . 8 nm are not filtered at all. 20 Flexible and linear-structured NPs show higher size thresholds compared to rigid and globular-structured NPs because of the rectangular shape of GBM slits. NPs larger than the renal filtration threshold will exhibit long blood half-lives (often desired) but have only three possible fates: metabolism to clearable components (desired), excretion by the liver into bile (desired), or uptake in the RES, resulting in long residence times in the body (undesired). 38, 44 NP metabolism is an area of investigation that is only now beginning to receive the attention it deserves. In general, though, a key feature of most NP systems is their extreme physicochemical stability. 22 Thus, in many cases, NP metabolism in the body is extremely slow, resulting in large ''exposure times.'' It should also be noted that the human body does not have cellular transporters for many elements used in NPs, such as cadmium, 45 which means that such elements are essentially ''stuck'' in the body after intravenous injection. The long residence time in the body for certain elements comprising NPs is a paramount concern of many regulatory agencies concerned with human health and the environment (see below).
Large NPs with a long blood half-life eventually undergo some level of hepatic uptake by either Kupffer cells (macrophages located in the liver) and/or hepatocytes. Depending on their chemical composition, some NPs can be metabolized in the liver to components that will undergo excretion into bile. In rare cases, hydrophilic, intact NPs . 8 nm in HD are capable of biliary excretion into bile, 18 although the efficiency of elimination is much lower than for renal filtration and the chemical rules mediating the process are not fully understood.
RES and Immune-Mediated Metabolism/Elimination
In general, large NPs (. 8 nm in HD) suffer from the problem of inevitable uptake by the RES, composed of phagocytic cells, primarily monocytes and macrophages, located in the reticular connective tissue of the liver, spleen, and bone marrow. 39, 43 In addition to size, surface charge plays a key role in RES uptake because the filtration barrier is covered with a layer of polyanionic glycoproteins, which repel most large anions. 39 Surface charge and hydrophobicity promote adsorption or opsonization by serum proteins present in the blood, which bind to foreign particles, such as some NPs, and increase recognition by phagocytic cells. 39 Serum protein binding also results in an effective increase in HD and can preclude renal clearance of NPs even if the HD would otherwise be small enough to permit it. 20 Depending on the chemical composition of the NPs, immune-mediated clearance can be a rapid or slow process. 46 In general, surface modification of NPs using biologically inert, hydrophilic, and neutral polymers such as polyethylene glycol (PEG) will slow the rate of clearance from the blood and uptake into the RES. 12 
Tumor-Targeting Strategies
There are essentially two ways to target an NP to malignant cells: active targeting using tumor-specific ligands and clearable NPs and passive targeting that relies on enhanced permeability and retention (EPR). 47, 48 We would argue that the former is difficult but effective and the latter is easy but essentially worthless.
Active targeting requires creating an NP that has biodistribution to the extracellular space of every tissue (both normal and tumor) and organ in the body, highaffinity binding to the malignant cell, significant clearance from nontumor tissue, and elimination from the body of that fraction of NP that does not bind to malignant cells. Based on what is presently known about NPs, ultrasmall agents with rapid renal clearance meet these criteria 40 but are difficult to construct and nullify most of the advantages of NPs (ie, large size).
EPR exploits the fact that tumors large enough to recruit a neovasculature (typically . 1 mm diameter) also have a dysfunctional lymphatic drainage system and will nonspecifically accumulate NPs injected into the bloodstream. 9 Unfortunately, the field of nanotechnology is doing itself a grave disservice, and wasting valuable grant dollars and time, by focusing on EPR over active targeting. First, EPR requires a tumor neovasculature, which does not appear until the tumor size exceeds < 1 mm in diameter. This precludes targeting malignant cells in micrometastases, which will grow and ultimately kill the patient. Requiring tumors to grow to a size where angiogenesis has occurred but before NP diagnosis or therapy is effective is nonsensical. Second, we already have a large body of clinical data from nanosized chemotherapeutics (see below) that prove that the EPR ''effect size'' is minimal in vivo. In fact, the main reason liposomal formulations of chemotherapeutics were approved is because of reduced toxicity, owing to altered biodistribution, and not because of improved efficacy. 49 Third, retention in tumors via EPR necessarily means poor elimination from the body (owing to a large HD and/or surface charge), resulting in eventual uptake by the RES, long body retention times, and a higher likelihood of NP toxicity.
Although EPR may play a role in limited clinical scenarios in which identification of a primary tumor, or large vascularized metastases, is desired, relying on it as a tumor targeting strategy simply avoids the inevitable conclusion: most NPs cannot be used for active targeting of micrometastases 50 and, therefore, will play a minimal role in cancer diagnosis and therapy.
Interference with Other Biomedical Imaging Modalities
In the context of clinical translation, care must be taken to ensure that NPs do not themselves interfere with other, unrelated imaging modalities. For example, a large, dense NP that provides contrast for MRI might introduce a reflection that alters the interpretation of ultrasonography. 51, 52 Similarly, an NP that provides optical contrast may alter tissue radiodensity and, ultimately, the interpretation of computed tomography (CT). 53 
Potential Toxicity of NPs
Safety is the paramount concern for any diagnostic or therapeutic agent administered to the human body. However, NPs generate chemical, biologic, and environmental concerns above and beyond those of conventional agents. Many NPs contain elements, such as gadolinium, cadmium, selenium, tellurium, arsenic, and lead, or their complexes, which are known to have acute or chronic toxicity in vertebrates. 45 Particularly concerning are reproductive risks, immunotoxicity, and carcinogenicity, which are manifested only after long periods of time. 54 Even when containing only carbon, the unique geometry of certain NPs has been shown to introduce unexpected biologic toxicity. [55] [56] [57] [58] Finally, disposal of certain NPs may be problematic because their remarkable chemical stability could lead to entrance into the water tables. 22, 59 Thus, even before the proposed advantages of nanotechnology are fully realized, 15, 60 increased public attention and concerns over short-and long-term toxicity abound. 58, 59, 61 Classes of NPs for Biomedical Imaging, Diagnostics, Therapeutics, and Theragnostics
The literature is replete with multifunctional metal-based, carbon-based, polymer-based, biologic-based, and lipidbased NPs that have been proposed for biomedical imaging, diagnostics, and/or therapeutics. NP classes described to date, along with their key advantages and disadvantages, are listed in Table 1 and are described in detail as follows.
Metal Oxide NPs
Spherical ferromagnetic NPs consisting of an iron (Fe) core and a polymeric coating have been used in biomedical imaging, cell tracking, and monitoring of drug delivery. 7, 11 Iron oxide NPs, synthesized from ferrites composed of maghemite (Fe 2 O 3 ) and magnetite (Fe 3 O 4 ) metal ions, are often classified according to their effective size and coating: monocrystalline iron oxide nanocolloid (MION; 5-30 nm), cross-linked iron oxide (CLIO; 10-50 nm), and superparamagnetic iron oxide (SPIO; . 50 nm). These NPs have been used extensively as contrast-enhancing probes for MRI. 21 Iron oxide NPs are primarily cleared from the blood by the RES and taken up by monocytes and macrophages, which limits their utility to the diagnosis of inflammatory and degenerative disorders associated with high macrophage activity, 62 or the replacement of normal lymph node architecture with metastatic cells. 63 To avoid opsonization and to effect adequate biodistribution and clearance for the desired clinical indication, the physicochemical properties of these NPs require optimization. 64 
Gold-Containing Nanostructures
Unique NP geometries created from gold include nanorods (a nano-object with two similar external dimensions in the nanoscale and the third dimension significantly larger than the other two external dimensions), nanofibers (flexible nanorods), nanoshells (hollow NPs), and nanocages (porous wall-covered nanoshell structures). 65 Goldcontaining nanostructures have been explored for various biomedical applications such as drug delivery, 66 imaging, 67 tumor therapy, 66, 68 radiation sensitization, 69 and sentinel lymph node mapping. 70 By adjusting the core and shell thickness, gold-containing NPs offer significant flexibility in tuning the wavelengths of optical absorption and scatter, from the visible to the near-infrared (NIR; 700-900 nm). [71] [72] [73] They also provide the ability to permit noninvasive photothermal ablation of tumors using ultrasound and microwaves in cases where surgery would be difficult. 67, 74 However, care must be taken to minimize damage to surrounding normal tissue, and because of their unique geometry, penetration into skin and other organs can cause dermatitis and irritation. 75 In addition, accumulation of gold salts in the body may cause other toxicity. 76 
Quantum Dots
Fluorescent semiconductor nanocrystals, or quantum dots (QDs), contain an inorganic core, and sometimes a shell, and an organic, biocompatible coating. Final HDs range from 5 to 50 nm. QDs have been used extensively in in vivo imaging as a replacement for small-molecule organic fluorophores and have been used to track biochemical processes and cancer metastases in living animals. 8, 77, 78 Compared to conventional small-molecule organic fluorophores, QDs often exhibit higher photostability, extinction coefficient, and quantum yield and can also provide broadband absorption, narrow and tunable emission spectra, and multivalent ligand conjugation. 8, 79, 80 Many QD chemical compositions have been shown to reach NIR emission, including InAs/ZnS, 18 InAsxP1-x/InP/ZnSe, 81 CdTe/CdSe, 79 and Cu-In-Se. 82 Because of their appropriate size (10-30 nm) and fluorescence, NIR QDs have extensively been used for sentinel lymph node mapping. 79, 81, [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] After surface functionalization using small molecules, peptides, proteins, or antibodies, NIR QDs are capable of detecting targets of interest in living animals. 10, 77, 93 Because of the need for at least one potentially toxic element to reach NIR wavelengths (eg, In, As, Cd, or Te) and their extreme in vivo stability if not cleared adequately, 94 clinical translation of NIR QDs remains stalled (discussed below).
Silica NPs
Silica is a popular component for developing biodegradable and biocompatible core-shell hybrid structured NPs because of its chemical and biologic inertness and thermal stability. [95] [96] [97] The crystallization and condensation reactions can be performed in aqueous systems at room temperature, which makes these NPs compatible with various heat-sensitive biomolecules that need to be incorporated into them. The charged surface permits silica colloids to be stable at high concentrations, and further modification of the surface can be accomplished using siloxane-based cross-linkers. In addition, the mesoporous silica structures permit reactants to perfuse through the shell and enter or leave the core based on their high surface area and tunable pore sizes. 98 Gold, silver, platinum, and many other metals can be used to compose silicabased nanoshells for use as biosensors, biomarkers, and other biomedical detectors. 99 For example, fluorophoreencapsulated silica NPs are being used as optical imaging agents with high fluorescence emission intensity, excellent photostability, and water solubility. 96 Questions regarding the elimination of silica-based NPs from the body and their potential toxicity remain unanswered. 21, 100 
Molecular Dots
Calcium phosphate NPs are small, biocompatible, multilayer nanocomposites that are more rigid than larger liposomal structures. Calcium phosphate core-shell NPs can be synthesized via robust and reproducible methods based on biomineralization of calcium phosphate around precipitated amphiphiles. NP formation can also be controlled using ion and surfactant concentrations, pH, ionic strength, and temperature. 101, 102 Because of their composition, calcium phosphate NPs have a lower likelihood of toxicity compared to other types of NPs. Because they are bioresorbable and biodegradable and diagnostic and therapeutic agents can be trapped in them during synthesis, they could potentially be used as universal carriers. Like most NPs, though, the final HD is large, in the range of 20 to 100 nm, and surface modifications can be difficult.
Carbon-Based NPs C 60 buckyballs and cylindrical single-walled or multiwalled carbon nanotubes are hollow containers that can readily accommodate a payload of diagnostic and/or therapeutic agents. The diameter of carbon nanotubes is between 3 and 100 nm, but the length to diameter ratio can be as high as 2.8 3 10 7 to 1. 103 Fullerenes and carbon nanotubes are composed solely of carbon atoms and are thus extremely hydrophobic, resulting in aggregation and nonspecific binding to plasma proteins. Efforts have been made to solubilize them in water via surface modification, including oxidation or conjugation to hydrophilic organic molecules. 104 After surface modification and purification, these water-soluble cylindrical nanostructures show the potential for biologic research because they retain their extraordinary strength, electrical properties, and thermal conductivities. Clinical translation, however, will be slowed by concerns over their potential toxicity and difficulties in chemical modification of their surface. 55, 57 Carbon nanotubes, in particular, have been difficult to evaluate because of heterogeneity in size, agglomeration, and sample purity. 105 Recent reports suggest that carbon nanotubes that cross the cell membrane or are retained in organs for long periods of time result in cell death and inflammation, including epithelioid granulomas and fibrotic reactions. 56, 106 Other reports suggest relatively low toxicity when samples are pure and used at a low dose. 107 
Nanowires
Metal-based semiconductor nanowires composed of silicon, carbon, and other materials are widely used as chemical and biologic sensors for high-throughput detection of proteins and DNA, 108, 109 as well as for the potential delivery of contrast agents into living cells. 110 For example, single-crystal structured silicon nanowires can be prepared as both p-and n-type materials as small as 2 to 5 nm, which perform better than planar silicon microelectronics. 111 However, the diameter of nanowires significantly increases up to 10 to 300 nm when a water-soluble coating is applied for in vivo compatability. 108 The needle-like shape of nanowires and carbon nanotubes, which are similar to asbestos fibers that cause mesothelioma, requires extreme caution if clinical translation is considered. 112 
Biologic NPs
Biologic NPs include nanoscale materials derived from biologic components such as peptides, proteins, enzymes, antibodies, lipoproteins, viruses, and natural polymers. Naturally derived NPs frequently demonstrate high biocompatibility and biodegradability, whereas manufactured NPs often elicit undesired bodily responses. 113 Collagen and hyaluronate, the main components of extracellular matrices, are the most widely used tissuederived natural polymers. Because they result in minimal inflammation, they can be used as biodegradable imaging probes after surface modification. 114 On the other hand, NIR fluorophore-conjugated proteins and antibodies also have potential as targeting probes for the evaluation of disease progress. 115 Additionally, owing to their long blood half-lives, albumin, lipoproteins, chitosan, dextran (a-1,6polyglucose), and dextrin (a-1,4-polyglucose) have also been used as templates for carrying drugs and contrast agents after chemical or physical adsorption. 24, 85, [116] [117] [118] [119] Alginate and agarose are also well-known biomaterials obtained from algae polysaccharide and are widely used in drug delivery and tissue engineering owing to their biocompatibility and low toxicity. In general, biologic polymers suffer from poor physical strength, difficulty in controlling the size and shape of NPs, difficulty in controlling degradation, and, in some cases, immunogenicity. 24 Physicochemical properties can be improved by chemical cross-linking or by using chemically modified polymers, but then the materials become nonnatural chemical entities.
Polymer Nanospheres
Biodegradable and biocompatible synthetic polymers such as polylactic acid (PLA), polylactide-co-glycolide (PLGA), polyvinyl alcohol, polyacrylic acid, polyvinyl pyrrolidone, polyethyleneimine, polyamino acids, poly-L-lysine, polyglutamic acid, polymalic acid, polyaspartamides, polymethylmethacrylate, polymethylcyanoacrylate, polyethylcyanoacrylate, polyisobutylcyanoacrylate, polyisohexylcyanoacrylate, and their copolymers have been extensively used to fabricate nanospheres for the delivery and controlled release of water-insoluble, hydrophobic drugs to sites of disease. 24, [120] [121] [122] [123] By coating these polymers with other functional polymers, such as PEG, poloxamines, poloxamers, or polysaccharides, ''smart'' polymer NPs can be produced, which release their payload only after application of a stimulus, such as pH, temperature, light, ionic strength, or chemical environment. [123] [124] [125] Coating inorganic-based NPs, such as Au, QDs, silica, and carbon nanotubes, with biocompatible polymers increases stability and blood half-life while minimizing and/or delaying RES uptake. 126 
Dendrimers
Dendrimers are spherical macromolecular NPs with highly branched (tree-like) internal structures. The interaction of dendrimers with the physiologic environment is mainly controlled by their terminal groups. Owing to their globular shape and internal cavities, dendrimers can encapsulate therapeutic agents either in their interior or on their surface. Over the last decade, polyamidoamine (PAMAM) dendrimers from a 1,2-diaminoethane core and polypropyleneimine dendrimers have been used in a wide variety of diagnostic and therapeutic applications because they are biocompatible, have high water solubility (hydrophilicity) and flexibility, have well-defined structures, and can be easily conjugated with targeting ligands or payload. [127] [128] [129] [130] [131] The HD of dendrimers can be controlled during chemical synthesis, and, importantly, some smallsized (# 5 nm) dendrimers can be cleared from the blood through renal excretion. 21, 66, 131 In general, though, dendrimers can be more expensive to produce than conventional polymers, require complex repetitive steps for synthesis, and can be difficult to scale up for production.
Liposomes
Because of their large payload capacity and straightforward synthesis, liposomes have long been used as delivery vehicles for hydrophilic and hydrophobic drugs, diagnostic agents, peptides, antibodies, hormones, and macromolecules after encapsulation by their lipid membranes. 24, 51, 116, [132] [133] [134] [135] [136] Although the synthesis of phospholipid bilayers does not require organic solvents, final products typically suffer from poor mechanical stability and burst leakage. 39, 43 By introducing inert, biodegradable coatings such as PEG, lipid membranes can be stabilized and further functionalized with various targeting/therapeutic moieties, including peptides, oligonucleotides, and proteins. 24, 116 However, every chemical addition to the original liposome increases HD even further and increases the likelihood of eventual RES uptake.
Fundamentals of Clinical Translation

Regulation of Nanomaterial-Based Products
Owing to ongoing safety concerns with the use of nanomaterials, the NNI launched the Nanotechnology Environmental and Health Implications Working Group (NEHIWG) to manage the potential risks associated with nanotechnology. 137 To help efficiently regulate potential nanotechnology research, the NEHIWG prepared the report ''NNI Strategy for Nanotechnology-Related Environmental, Health, and Safety Research'' in 2008. 138 The strategy identified five priority areas for environmental, health and safety research and for coordination of interested agencies 139 140 Among the federally funded institutions, the FDA is authorized to regulate a wide range of products, such as drugs and devices for humans and animals and biologic products for humans under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act.
The key point to understand is that the clinical translation of NPs requires a complete understanding of the relationship between the human body and particle size, composition, formulation, supramolecular structure, chemical reactivity, and biomechanical strength and stability, as detailed in Table 2 . It is also important to recognize that the FDA performs its regulatory role on a ''product-byproduct'' basis and that its approach to a particular product depends on the type of approval required: (1) products subjected to premarket approval (pharmaceuticals, high-risk medical devices, food additives, colors, and biologic products), (2) products subjected to postmarket surveillance (such as foods, cosmetics, radiation-emitting 
FDA-Approved Nanomaterial-Based Diagnostic and Therapeutic Agents
There is much to learn from those nanomaterial-based agents already approved by the FDA ( Table 3 ). The first is that regulatory approvals for nanomaterial-based agents are infrequent, averaging less than one per year over the last two decades, with no trend toward an increasing frequency. Second, each of the approved agents offered some quantifiable advantage over the nonnanomaterial that they sought to replace. Third, virtually all of the materials are organic. The only metal-based agent not administered as a microdose is composed of Fe, an element that in moderate quantities is required for red blood cell production and is therefore acceptable if not eliminated (excreted) completely from the body. Finally, given the costs associated with regulatory approval, all but one of the agents are therapeutics, where market sizes are larger and repeated dosing guarantees an extended cash flow. Even though approved, none of these NPs are ideal. Lipid-based carriers pose several challenges, such as instability of the carrier, initial burst drug release, and rapid blood clearance by the RES, mostly the liver and spleen, in a short period of time. 24, 123, 142 To improve the stability and prevent opsonization by the liver, the surface of liposomes has been coated with hydrophilic and inert polymers, mostly PEG. Caelyx/Doxil and DaunoXome/ Myocet, for example, are PEGylated liposome formulations for delivering doxorubicin showing enhanced circulation times and EPR effect for sustained drug release to the target. Overall, the HD of currently approved agents is extremely large and precludes elimination through renal filtration. Feridex, for example, an FDA-approved diagnostic agent composed of ion oxide NPs (SPIO), has a diameter of 15 nm by transmission electron microscopy and a final HD of < 50 nm owing to the organic coating required for blood solubility and biocompatibility.
An added complexity when trying to translate new chemical entities to the clinic is that the FDA classifies certain combinations of conventional drugs as NPs. Bexxar (mAb-I-131), Mylotarg (mAb-chemotherapeutic), Zevalin (mAb-I-111), and even the small-molecule Gd-DTPA all meet the FDA's definition of NPs because they are composed of two different components that together create a new functionality. The same is true for coating a conventional therapeutic with an inert polymer, such as PEG. Classification as an NP can become quite costly if it triggers additional preclinical testing that was not required for the individual components themselves.
NP Structural Considerations for Clinical Translation
Although the unusually small size of NPs renders their in vivo behavior unique, this same small size can make them potentially dangerous to human health. NPs not only are able to evade detection by the body's immune system, they also, under rare circumstances, have the ability to cross the BBB. 31, 143 The most common route of NP administration is intravenous. Once in the bloodstream, foreign substances, such as NPs, are often recognized by phagocytes of the RES. However, some NPs , 100 nm in HD are not efficiently absorbed by phagocytes and thus can move more freely throughout the body. 143 The surface reactivity of such NPs can also cause chemical damage to surrounding tissues. When inhaled, micron-sized particles deposit in the central airways; however, inhaled NPs deposit in the lung periphery, causing much greater inflammation. 112 Finally, just possessing nanoscale dimensions may, in and of itself, be toxic. Needle-shaped carbon nanotubes, nanowires, and Year of Approval Product Name Nanoparticles for Biomedical Imaging nanofibers, for example, resemble the geometry of crocidolite asbestos, which can cause fibrotic lung disease and rare tumors, such as mesothelioma. 112, 144 Thus, a comprehensive analysis of any new nanomaterial to be administered to the human body must be undertaken to avoid unintended side effects. Biodistribution and clearance profiles are of paramount importance for such side effects. 143 In particular, nonbiodegradable NPs that accumulate in certain organs, mostly in the RES, can cause potential harm, including immunemediated toxicity, teratogenicity, and carcinogenicity.
The key considerations for NP interaction with the human body are provided in Table 2 .
Government-Sponsored Resources Available to Assist with NP Clinical Translation
Given the complexities associated with clinical translation of NPs, investigators are fortunate to have a variety of government-sponsored resources available to them.
Food and Drug Administration
The FDA is a member of the Nano-scale Science and Engineering Technology (NSET) subcommittee of the National Science and Technology Council (NSTC) Committee on Technology and cochairs with the NIOSH the NSET Working Group on Nanomaterials Environmental and Health Implications (NEHI) to define new test methods to assess the safety of these products. 145 The FDA also assists with the evaluation of nanomaterial toxicity studies supported by the National Institute of Environmental Health Sciences (NIEHS) and the National Toxicology Program (NTP). 146 Presently, there are no testing requirements specific to nanotechnology products; however, the CDER and the FDA consider that existing regulatory requirements may be adequate for most nanotechnology products that they currently regulate. 147 If research identifies toxicologic risks that are unique to certain nanomaterials, additional testing requirements may become necessary. 145 
National Cancer Institute
In 2004, the National Cancer Institute (NCI) initiated the Alliance for Nanotechnology in Cancer to develop and translate cancer-related nanotechnology research into clinical practice. 148 To guide the implementation of the NCI Alliance, a cancer nanotechnology plan has been developed by establishing four major programs: 149 to perform and standardize the preclinical characterization (pharmacology, toxicology, and efficacy testing) of nanodevices (in conjunction with the FDA) to allow accelerated regulatory review and translation of basic research into the clinical domain. The NCL is also conducting material characterization and toxicology assessment for the development of cancer therapeutic drugs and will provide the eventual drug sponsor with data to understand the toxicologic risk that could be included as part of a New Drug Application to the FDA.
National Nanotechnology Initiative
The NNI reports to the White House Office of Science and Technology Policy (OSTP) and informs the president and Congress through the OSTP regarding the investment in nanotechnology to (1) keep the United States at the forefront of this important and emerging industry and (2) reduce duplication of efforts across the many US agencies. 150 The NNI identified areas of health-related research that are ongoing in the US government and recommends areas where additional resources should be invested (NNI, 2008) . 138 Identification of the potential toxicologic hazards of nanomaterials within the US government is being funded within and through the following agencies: The initial parameters of greatest concern to the NTP are size, shape, surface chemistry, and composition. 146 Ongoing research activities are focusing initially on four classes of nanoscale materials: (1) metal oxides; (2) fluorescent crystalline semiconductors (QDs); (3) fullerenes; and (4) carbon nanotubes. 146 NTP-published studies on the inhalation of nanomaterials suggest that particle size and distribution can impact toxicity equally, if not more so, than chemical composition. 146 Surface properties can be changed by coating NPs with different materials such as PEG or zwitterionic organic materials, but such a chemical modification also influences the size of the particle. 20 The interaction of surface area and particle composition in eliciting biologic responses adds an extra dimension of complexity in evaluating potential adverse events that may result from exposure to nanomaterials. These engineered NPs actually distribute in the body in unpredictable ways. 147 The FDA is taking significant steps to address the safety of nanomaterials as a function of their size, surface chemistry, surface physics, route of administration, and ADME (absorption, distribution, metabolism, elimination). 150, 151 The FDA is also concerned that the current assays and tests that the agency requires sponsors to conduct in support of product safety are adequate to detect adverse biologic and toxicologic events. Because of these issues, the FDA is in the process of submitting the following Scientific Issues Nomination to the NTP: (1) examine the role of nanoscale size and surface coating on the fate (ADME) of nanomaterials in a rodent animal model; (2) examine the ability of nanomaterials to pass through the BBB and enter the CNS; (3) examine a select set of required tests to determine their ability to detect adverse biologic or toxicologic effects when challenged with nanomaterials; and (4) use colloidal gold and silver NPs as test agent nanomaterials. 150 
Challenges and Perspective
The fundamental question that one must answer before exploring any NP-based idea is whether the ''nanoscale'' is actually needed to solve the clinical problem at hand. Given their relatively large size, high retention in the body, and potential toxicity, many classes of NPs introduce more complexity than they may be worth. In addition, intellectual property constraints surrounding certain NPs (discussed below for QDs) often preclude efficient clinical translation.
Take, for example, an NP containing the atom gold. Gold is a potent immunotoxin that has been used for almost a century in small amounts to treat rheumatoid arthritis. It is concerning, therefore, that gold-based nanoparticles could decompose and release gold atoms in an immunotoxic form. Moreover, gold has a linear attenuation coefficient that is 250 times higher than soft tissue. Thus, even a small fraction of gold deposited in normal organs could alter radiodensity and render CT uninterpretable. If the clinical benefits provided by goldbased NPs outweigh these clinical harms, then gold-based NPs might be viable for clinical translation. However, if there were a technology that accomplishes the same result without employing NPs, then it would be difficult to justify clinical translation.
Design Considerations of NPs Destined for Clinical Translation
The translation of many NPs into the clinic is presently being stymied by the (reasonable) mandate of the FDA that metal-containing NPs not be retained in the body. The longer an NP is retained in the body, the larger the area under the concentration-time curve and the higher the likelihood of potential toxicity. This was one of the primary motivators for our group to develop ultrasmall QDs that are cleared rapidly by renal filtration and eliminated in urine and to develop organic surface coatings that minimize nonspecific uptake and retention of NPs after intravenous injection. 20, 40 In the context of the current regulatory framework, and based on what is now known about how NPs interact with the human body, we propose three simple criteria to help guide clinical translation of NPs (Table 4 ). We would argue that an ideal NP, with a high likelihood of clinical translation, would meet all three criteria, whereas NPs meeting only one or two criteria might eventually encounter prohibitive regulatory hurdles. Of note, the third criterion concerning complete elimination from the body through renal clearance is not satisfied by some currently FDA-approved agents, such as iron oxide NPs and liposomes, because their components are relatively nontoxic. However, one must wonder whether the performance of these NPs (ie, lower background) could be improved by engineering them for efficient renal clearance.
Objective Assessment of QDs and Their Viability for Clinical Translation
To summarize and synthesize the key points discussed in this review, consider the case of QDs. When first developed, there was huge excitement in the biomedical imaging community. Their broadband absorbance in the blue, high photostability and chemical stability, extraordinary quantum yields, and tunability from the ultraviolet to the infrared were all touted as being revolutionary. However, after about a decade of investigation, many of these ''features'' of QDs are now classifiable as reality, myth, or indeterminate (Table 5) .
Although the tunability of emission wavelength is a major advantage over small-molecule fluorophores, redder wavelengths require larger structures, which negatively affect biodistribution and clearance. 18 Not all emission wavelengths are achievable with nontoxic elements. NIR wavelengths, in particular, suffer from the requirement for one or more toxic elements, and some syntheses are so dangerous that they should be attempted only by expert chemists. Although QD photostability is a nice feature, the excitation fluence rates that can actually be used in a clinical environment are orders of magnitude lower than QD limits and are so low that photobleaching of most small-molecule fluorophores can be avoided. 152 Broadband absorption of QDs is actually nullified by Rayleigh scattering tissue, causing the excitation profile to resemble a small-molecule fluorophore. 153 Moreover, as a function of molecular volume, QDs underperform small molecules with respect to extinction coefficient and total photon yield. 153 Finally, most QDs do not achieve a final HD compatible with renal filtration, their quantum yield in serum tends to be one-quarter that obtained in organic solvent, and their stability in warm serum is often variable. When even a 5.5 nm QD is compared directly to a 1 kDa small-molecule NIR fluorophore (Figure 2) , it becomes apparent that the optical performance of QDs comes at a steep price that may, or may not, be worth the added complexity. Nevertheless, if careful attention is paid to formulation, final HD, and 
Criterion Consideration
Formulation Composed of completely nontoxic materials and/ or biodegradability to clearable (renal or hepatic) components and Surface charge Zwitterionic or neutral organic surface coatings to minimize penetration of cellular membranes, nonspecific tissue/organ uptake, and binding to serum proteins (unless only EPR-based uptake is desired) and, preferably, Size and shape Hydrodynamic diameter of NPs or degradation products # 5.5 nm to facilitate complete renal elimination in a short period of time EPR 5 enhanced permeability and retention; NP 5 nanoparticle. surface charge, it is possible to develop QDs that are capable of targeting tumors efficiently after intravenous injection while being eliminated completely from the body through renal filtration ( Figure 3 ). 40 So, if one already has a renally cleared, highperforming QD that permits image-guided surgery of malignant tumors, why not translate it to the clinic? The first problem is one of intellectual property. A single patent in the field precludes ''freedom to practice'' such an invention without permission and cooperation from a certain for-profit company. Second, to satisfy the regulatory requirements of complete elimination from the body, the QD is necessarily small. Thus, its extinction coefficient is not significantly different from that of a well-designed small-molecule fluorophore, and the same (or better) imaging can be achieved using such a small molecule. Third, current Good Manufacturing Practices (cGMP) synthesis of the QD shown in Figure 3 would be significantly more difficult than an equivalent small molecule. Finally, regulatory scrutiny of a metalcontaining QD and the long-term toxicology tests that would undoubtedly be required would add significant cost to clinical translation. The alternative is a class of small-molecule NIR fluorophores, the heptamethine indocyanines, whose prototype indocyanine green has an extraordinary, 50+ year safety record in humans and a facile cGMP synthesis.
Conclusion
Like any new technology, nanotechnology has experienced the typical sequence of unbridled excitement, relentless criticism, and now careful introspection. Is it the answer to all or even many problems in biomedical imaging? Absolutely not. Might it play a role in the diagnosis and/ or treatment of certain human conditions and diseases? It already has. As discussed in this review, the clinical translation of many types of NPs will be impeded by fundamental limitations of human physiology (ie, vessel pore size, renal and hepatic clearance, RES), potential toxicity, and/or interference with other medical tests. At the very least, we suggest that NPs considered for clinical Figure 2 . Physicochemical and optical properties of quantum dots (QDs) versus small molecules. A, Relative size differences between a 5.5 nm QD (left) and a typical 1 kDa heptamethine indocyanine small-molecule nearinfrared fluorophore (right). Shown below each are the ranges in hydrodynamic diameters (HDs) of nontargeted derivatives described in the literature. To the right of each (in orange) are shown the contribution of various targeting ligands, described in the literature, to final HD. B, Summary comparison of key physicochemical and optical properties of inorganic/organic hybrid QDs versus organic small-molecule fluorophores. RES 5 reticuloendothelial system. translation in biomedical imaging should meet as many of the ''Choi criteria'' (see Table 4 ) as are needed for the particular application. But, prior to beginning any investigation, we urge careful thought about whether the solution cannot actually be found using atomic scale rather than nanoscale molecules. Figure 3 . Ultrasmall zwitterionic nanoparticles and their rapid renal clearance after effective tumor targeting. 40 A, Chemical composition of QD-CW-cRGD (CW800-conjugated CdSe(CdZnS) quantum dots [QDs] with cyclic RGDyK peptide targeting ligands). B, Ten pmol/g of QD-CW-cRGD was injected into tumor-bearing mice and observed at 4 hours postinjection. Shown are merged images of color video and near-infrared fluorescence (pseudocolored in lime green) acquired using the FLARE TM imaging system. 166 An a v b 3 -positive M21 tumor (+) and an a v b 3 -negative M21-L tumor (2) are indicated, as are the kidneys and bladder after surgical exposure.
